Aducanumab
- Generic Name
- Aducanumab
- Brand Names
- Aduhelm
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1384260-65-4
- Unique Ingredient Identifier
- 105J35OE21
- Background
Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction ...
- Indication
Aducanumab is indicated for the treatment of Alzheimer’s disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were ...
- Associated Conditions
- Alzheimer's Disease (AD)
- Associated Therapies
- -
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Ali Rezai
- Target Recruit Count
- 15
- Registration Number
- NCT05469009
- Locations
- 🇺🇸
West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1512
- Registration Number
- NCT05310071
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
- Conditions
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT05108922
- Locations
- 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States
🇺🇸Conquest Research, Winter Park, Florida, United States
A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT04924140
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1696
- Registration Number
- NCT04241068
- Locations
- 🇨🇦
Montreal Neurological Institute Clinical Research Unit, Montréal, Quebec, Canada
🇫🇷CHU Lille - Hopital Roger Salengro, Lille Cedex, Nord, France
🇫🇷Hôpital Lariboisière, Paris cedex 10, Paris, France
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT03639987
- Locations
- 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸Pacific Research Network, Inc, San Diego, California, United States
🇺🇸Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT02782975
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 21
- Registration Number
- NCT02434718
- Locations
- 🇯🇵
Research Site, Kyoto, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.